Abstract
Aberrant DNA methylation of cell-free circulating DNA (cfDNA) has recently gained attention for its use as biomarker in cancer diagnosis, prognosis, and prediction of therapeutic response. Quantification of cfDNA methylation levels requires methods with high sensitivity and specificity due to low amounts of cfDNA available in plasma, high degradation of cfDNA, and/or contamination with genomic DNA. To date, several approaches for measuring cfDNA methylation have been established, including quantitative methylation-specific PCR (qMSP), which represents a simple, fast, and cost-effective technique that can be easily implemented into clinical practice. In this chapter, we provide a detailed protocol for SYBR Green qMSP analysis which is currently used in our laboratory for cfDNA methylation detection. Useful information regarding successful qMSP primers design are also provided.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Salvi S, Gurioli G, De Giorgi U, Conteduca V, Tedaldi G, Calistri D, Casadio V (2016) Cell-free DNA as a diagnostic marker for cancer: current insights. Onco Targets Ther 9:6549–6559. https://doi.org/10.2147/OTT.S100901
Chen K, Zhang H, Zhang L-N, Ju S-Q, Qi J, Huang D-F, Li F, Wei Q, Zhang J (2013) Value of circulating cell-free DNA in diagnosis of hepatocellular carcinoma. World J Gastroenterol 19(20):3143–3149. https://doi.org/10.3748/wjg.v19.i20.3143
Cheuk IWY, Shin VY, Kwong A (2017) Detection of methylated circulating DNA as noninvasive biomarkers for breast cancer diagnosis. J Breast Cancer 20(1):12–19. https://doi.org/10.4048/jbc.2017.20.1.12
Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV (2013) The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci 14(9):18925–18958. https://doi.org/10.3390/ijms140918925
Schwarzenbach H, Pantel K (2015) Circulating DNA as biomarker in breast cancer. Breast Cancer Res 17:136. https://doi.org/10.1186/s13058-015-0645-5
Diaz LA Jr, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32(6):579–586. https://doi.org/10.1200/jco.2012.45.2011
Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11(6):426–437. https://doi.org/10.1038/nrc3066
Fleischhacker M, Schmidt B (2007) Circulating nucleic acids (CNAs) and cancer—a survey. Biochim Biophys Acta 1775(1):181–232. https://doi.org/10.1016/j.bbcan.2006.10.001
Boscolo-Rizzo P, Furlan C, Lupato V, Polesel J, Fratta E (2017) Novel insights into epigenetic drivers of oropharyngeal squamous cell carcinoma: role of HPV and lifestyle factors. Clin Epigenetics 9:124. https://doi.org/10.1186/s13148-017-0424-5
Fratta E, Montico B, Rizzo A, Colizzi F, Sigalotti L, Dolcetti R (2016) Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. Oncotarget 7(35):57327–57350. https://doi.org/10.18632/oncotarget.10033
Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K, Kozuki T, Aoe M, Kiura K, Ueoka H, Tanimoto M (2005) Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 11(3):1219–1225
Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD (2015) Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? a report of the Association for Molecular Pathology. J Mol Diagn 17(3):209–224. https://doi.org/10.1016/j.jmoldx.2015.02.001
Perrone F, Lampis A, Bertan C, Verderio P, Ciniselli CM, Pizzamiglio S, Frattini M, Nucifora M, Molinari F, Gallino G, Gariboldi M, Meroni E, Leo E, Pierotti MA, Pilotti S (2014) Circulating free DNA in a screening program for early colorectal cancer detection. Tumori 100(2):115–121. https://doi.org/10.1700/1491.16389
Madhavan D, Wallwiener M, Bents K, Zucknick M, Nees J, Schott S, Cuk K, Riethdorf S, Trumpp A, Pantel K, Sohn C, Schneeweiss A, Surowy H, Burwinkel B (2014) Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat 146(1):163–174. https://doi.org/10.1007/s10549-014-2946-2
Xia S, Huang CC, Le M, Dittmar R, Du M, Yuan T, Guo Y, Wang Y, Wang X, Tsai S, Suster S, Mackinnon AC, Wang L (2015) Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls. Lung Cancer 90(1):78–84. https://doi.org/10.1016/j.lungcan.2015.07.002
Li Z, Guo X, Tang L, Peng L, Chen M, Luo X, Wang S, Xiao Z, Deng Z, Dai L, Xia K, Wang J (2016) Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing. Tumour Biol 37(10):13111–13119. https://doi.org/10.1007/s13277-016-5190-z
Barault L, Amatu A, Siravegna G, Ponzetti A, Moran S, Cassingena A, Mussolin B, Falcomata C, Binder AM, Cristiano C, Oddo D, Guarrera S, Cancelliere C, Bustreo S, Bencardino K, Maden S, Vanzati A, Zavattari P, Matullo G, Truini M, Grady WM, Racca P, Michels KB, Siena S, Esteller M, Bardelli A, Sartore-Bianchi A, Di Nicolantonio F (2017) Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut. https://doi.org/10.1136/gutjnl-2016-313372
Horning AM, Awe JA, Wang CM, Liu J, Lai Z, Wang VY, Jadhav RR, Louie AD, Lin CL, Kroczak T, Chen Y, Jin VX, Abboud-Werner SL, Leach RJ, Hernandez J, Thompson IM, Saranchuk J, Drachenberg D, Chen CL, Mai S, Huang TH (2015) DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. Prostate 75(15):1790–1801. https://doi.org/10.1002/pros.23052
Wang J, Han X, Sun Y (2017) DNA methylation signatures in circulating cell-free DNA as biomarkers for the early detection of cancer. Sci China Life Sci 60(4):356–362. https://doi.org/10.1007/s11427-016-0253-7
Warton K, Samimi G (2015) Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci 2:13. https://doi.org/10.3389/fmolb.2015.00013
Issa J-P (2012) DNA methylation as a clinical marker in oncology. J Clin Oncol 30(20):2566–2568. https://doi.org/10.1200/jco.2012.42.1016
Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clement N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA, De Preter K, Speleman F, Vandesompele J (2016) Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma. Oncotarget 7(2):1960–1972. https://doi.org/10.18632/oncotarget.6477
Exner R, Pulverer W, Diem M, Spaller L, Woltering L, Schreiber M, Wolf B, Sonntagbauer M, Schröder F, Stift J, Wrba F, Bergmann M, Weinhäusel A, Egger G (2015) Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkers. Br J Cancer 113(7):1035–1045. https://doi.org/10.1038/bjc.2015.303
Hao X, Luo H, Krawczyk M, Wei W, Wang W, Wang J, Flagg K, Hou J, Zhang H, Yi S, Jafari M, Lin D, Chung C, Caughey BA, Li G, Dhar D, Shi W, Zheng L, Hou R, Zhu J, Zhao L, Fu X, Zhang E, Zhang C, Zhu J-K, Karin M, Xu R-H, Zhang K (2017) DNA methylation markers for diagnosis and prognosis of common cancers. Proc Natl Acad Sci. https://doi.org/10.1073/pnas.1703577114
Jeschke J, Bizet M, Desmedt C, Calonne E, Dedeurwaerder S, Garaud S, Koch A, Larsimont D, Salgado R, Van den Eynden G, Willard Gallo K, Bontempi G, Defrance M, Sotiriou C, Fuks F (2017) DNA methylation-based immune response signature improves patient diagnosis in multiple cancers. J Clin Invest 127(8):3090–3102. https://doi.org/10.1172/jci91095
Pineda B, Diaz-Lagares A, Perez-Fidalgo JA, Alonso E, Sandoval J, Gonzalez I, Crujeiras A-B, Burgues O, Esteller M, Lluch A, Eroles P (2015) DNA methylation signature to identify treatment response in triple negative breast cancer. J Clin Oncol 33(15_Suppl):1079. https://doi.org/10.1200/jco.2015.33.15_suppl.1079
Shen S, Wang G, Shi Q, Zhang R, Zhao Y, Wei Y, Chen F, Christiani DC (2017) Seven-CpG-based prognostic signature coupled with gene expression predicts survival of oral squamous cell carcinoma. Clin Epigenetics 9:88. https://doi.org/10.1186/s13148-017-0392-9
Strand SH, Orntoft TF, Sorensen KD (2014) Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci 15(9):16544–16576. https://doi.org/10.3390/ijms150916544
Sigalotti L, Covre A, Fratta E, Parisi G, Sonego P, Colizzi F, Coral S, Massarut S, Kirkwood JM, Maio M (2012) Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J Transl Med 10:185. https://doi.org/10.1186/1479-5876-10-185
Jiang P, Chan CWM, Chan KCA, Cheng SH, Wong J, Wong VW-S, Wong GLH, Chan SL, Mok TSK, Chan HLY, Lai PBS, Chiu RWK, Lo YMD (2015) Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci 112(11):E1317–E1325. https://doi.org/10.1073/pnas.1500076112
Parpart-Li S, Bartlett B, Popoli M, Adleff V, Tucker L, Steinberg R, Georgiadis A, Phallen J, Brahmer J, Azad N, Browner I, Laheru D, Velculescu VE, Sausen M, Diaz LA Jr (2017) The effect of preservative and temperature on the analysis of circulating tumor DNA. Clin Cancer Res 23(10):2471–2477. https://doi.org/10.1158/1078-0432.ccr-16-1691
Sherwood JL, Corcoran C, Brown H, Sharpe AD, Musilova M, Kohlmann A (2016) Optimised pre-analytical methods improve KRAS mutation detection in circulating tumour DNA (ctDNA) from patients with non-small cell lung cancer (NSCLC). PLoS One 11(2):e0150197. https://doi.org/10.1371/journal.pone.0150197
Kang Q, Henry NL, Paoletti C, Jiang H, Vats P, Chinnaiyan AM, Hayes DF, Merajver SD, Rae JM, Tewari M (2016) Comparative analysis of circulating tumor DNA stability in K3EDTA, Streck, and CellSave blood collection tubes. Clin Biochem 49(18):1354–1360. https://doi.org/10.1016/j.clinbiochem.2016.03.012
Toro PV, Erlanger B, Beaver JA, Cochran RL, VanDenBerg DA, Yakim E, Cravero K, Chu D, Zabransky DJ, Wong HY, Croessmann S, Parsons H, Hurley PJ, Lauring J, Park BH (2015) Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clin Biochem 48(15):993–998. https://doi.org/10.1016/j.clinbiochem.2015.07.097
Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, Fuchs CS (2006) Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 8(2):209–217. https://doi.org/10.2353/jmoldx.2006.050135
Sepulveda AR, Jones D, Ogino S, Samowitz W, Gulley ML, Edwards R, Levenson V, Pratt VM, Yang B, Nafa K, Yan L, Vitazka P (2009) CpG methylation analysis—current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. J Mol Diagn 11(4):266–278. https://doi.org/10.2353/jmoldx.2009.080125
Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M (2004) Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine. Cancer Res 64(24):9167–9171. https://doi.org/10.1158/0008-5472.can-04-1442
Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 89(5):1827–1831
Darst RP, Pardo CE, Ai L, Brown KD, Kladde MP (2010) Bisulfite sequencing of DNA. In: Ausubel FM et al (eds) Current protocols in molecular biology. Chapter 7, Unit 7.9:1–17. https://doi.org/10.1002/0471142727.mb0709s91
Snyder Matthew W, Kircher M, Hill Andrew J, Daza Riza M, Shendure J (2016) Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164(1):57–68. https://doi.org/10.1016/j.cell.2015.11.050
Yi S, Long F, Cheng J, Huang D (2017) An optimized rapid bisulfite conversion method with high recovery of cell-free DNA. BMC Mol Biol 18(1):24. https://doi.org/10.1186/s12867-017-0101-4
Holmes EE, Jung M, Meller S, Leisse A, Sailer V, Zech J, Mengdehl M, Garbe L-A, Uhl B, Kristiansen G, Dietrich D (2014) Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urine. PLoS One 9(4):e93933. https://doi.org/10.1371/journal.pone.0093933
Kurdyukov S, Bullock M (2016) DNA methylation analysis: choosing the right method. Biology 5(1):3. https://doi.org/10.3390/biology5010003
Bryzgunova OE, Laktionov PP (2017) [Current methods of extracellular DNA methylation analysis]. Mol Biol (Mosk) 51(2):195–214. https://doi.org/10.7868/s0026898417010074
Olek A, Oswald J, Walter J (1996) A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res 24(24):5064–5066. https://doi.org/10.1093/nar/24.24.5064
Delpu Y, Cordelier P, Cho W, Torrisani J (2013) DNA methylation and cancer diagnosis. Int J Mol Sci 14(7):15029
Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28(8):E32
Mazurek AM, Fiszer-Kierzkowska A, Rutkowski T, Skladowski K, Pierzyna M, Scieglinska D, Wozniak G, Glowacki G, Kawczynski R, Malusecka E (2013) Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma. Cancer Biomark 13(5):385–394. https://doi.org/10.3233/cbm-130371
Maggi EC, Gravina S, Cheng H, Piperdi B, Yuan Z, Dong X, Libutti SK, Vijg J, Montagna C (2018) Development of a method to implement whole-genome bisulfite sequencing of cfDNA from cancer patients and a mouse tumor model. Front Genet 9:6. https://doi.org/10.3389/fgene.2018.00006
Skrypkina I, Tsyba L, Onyshchenko K, Morderer D, Kashparova O, Nikolaienko O, Panasenko G, Vozianov S, Romanenko A, Rynditch A (2016) Concentration and methylation of cell-free DNA from blood plasma as diagnostic markers of renal cancer. Dis Markers 2016:10. https://doi.org/10.1155/2016/3693096
Vizza E, Corrado G, De Angeli M, Carosi M, Mancini E, Baiocco E, Chiofalo B, Patrizi L, Zampa A, Piaggio G, Cicchillitti L (2018) Serum DNA integrity index as a potential molecular biomarker in endometrial cancer. J Exp Clin Cancer Res 37(1):16. https://doi.org/10.1186/s13046-018-0688-4
Davidović RS, Božović AM, Mandušić VL, Krajnović MM (2014) Methylation-specific PCR: four steps in primer design. Cent Eur J Biol 9(12):1127–1139. https://doi.org/10.2478/s11535-014-0324-z
Illingworth RS, Bird AP (2009) CpG islands—‘A rough guide’. FEBS Lett 583(11):1713–1720. https://doi.org/10.1016/j.febslet.2009.04.012
Asmar F, Søgaard A, Grønbæk K (2015) Chapter 2—DNA methylation and hydroxymethylation in cancer A2. In: Gray SG (ed) Epigenetic cancer therapy. Academic Press, Boston, MA, pp 9–30. https://doi.org/10.1016/B978-0-12-800206-3.00002-1
Hernandez-Garcia CM, Finer JJ (2014) Identification and validation of promoters and cis-acting regulatory elements. Plant Sci 217–218:109–119. https://doi.org/10.1016/j.plantsci.2013.12.007
Li L-C, Dahiya R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18(11):1427–1431. https://doi.org/10.1093/bioinformatics/18.11.1427
Levin JD, Fiala D, Samala MF, Kahn JD, Peterson RJ (2006) Position-dependent effects of locked nucleic acid (LNA) on DNA sequencing and PCR primers. Nucleic Acids Res 34(20):e142. https://doi.org/10.1093/nar/gkl756
Gustafson KS (2008) Locked nucleic acids can enhance the analytical performance of quantitative methylation-specific polymerase chain reaction. J Mol Diagn 10(1):33–42. https://doi.org/10.2353/jmoldx.2008.070076
Hattori N, Ushijima T (2011) Chapter 8—Analysis of gene-specific DNA methylation A2. In: Tollefsbol T (ed) Handbook of epigenetics. Academic Press, San Diego, CA, pp 125–134. https://doi.org/10.1016/B978-0-12-375709-8.00008-3
Sorber L, Zwaenepoel K, Deschoolmeester V, Roeyen G, Lardon F, Rolfo C, Pauwels P (2017) A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma. J Mol Diagn 19(1):162–168. https://doi.org/10.1016/j.jmoldx.2016.09.009
Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, Hoon DSB (2006) Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 24(26):4270–4276. https://doi.org/10.1200/jco.2006.05.9493
Furlan C, Polesel J, Barzan L, Franchin G, Sulfaro S, Romeo S, Colizzi F, Rizzo A, Baggio V, Giacomarra V, Dei Tos AP, Boscolo-Rizzo P, Vaccher E, Dolcetti R, Sigalotti L, Fratta E (2017) Prognostic significance of LINE-1 hypomethylation in oropharyngeal squamous cell carcinoma. Clin Epigenetics 9:58. https://doi.org/10.1186/s13148-017-0357-z
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Sigalotti, L., Covre, A., Colizzi, F., Fratta, E. (2019). Quantitative Methylation-Specific PCR: A Simple Method for Studying Epigenetic Modifications of Cell-Free DNA. In: Casadio, V., Salvi, S. (eds) Cell-free DNA as Diagnostic Markers. Methods in Molecular Biology, vol 1909. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8973-7_11
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8973-7_11
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8972-0
Online ISBN: 978-1-4939-8973-7
eBook Packages: Springer Protocols